peroxisom
proliferatoractiv
receptor
ppar
nuclear
ligandactiv
transcript
factor
includ
three
subtyp
name
drug
target
ppar
mainli
includ
rosiglitazon
pioglitazon
use
antidiabet
drug
also
possess
antiinflammatori
antineoplast
agonist
fenofibr
bezafibr
use
antilipem
drug
figur
rosiglitazon
pioglitazon
shown
side
effect
clinic
use
liver
function
abnorm
edema
weight
especi
nissen
report
cardiac
safeti
rosiglitazon
show
singli
select
agon
enhanc
insulin
sensit
therapeut
effect
insulin
metabol
also
caus
edema
weight
gain
potenti
risk
heart
failur
recent
year
novel
ppar
concept
appear
antidiabet
drug
research
area
multitarget
cooper
dual
agonist
pan
agonist
multitarget
agonist
could
cooper
improv
glucos
lipid
metabol
could
effect
control
blood
sugar
also
reduc
content
triglycerid
free
fatti
acid
lowdens
lipoprotein
well
increas
highdens
lipoprotein
concentr
thu
prevent
effect
cardiovascular
complic
type
diabet
patient
multitarget
ppar
agonist
enter
clinic
trial
repres
promis
ppar
drug
pharmacophor
ppar
agonist
consist
polar
head
linker
hydrophob
tail
polar
head
ppar
agonist
could
form
hydrogen
bond
tyr
residu
region
produc
transactiv
effect
hydrophob
tail
ppar
agonist
could
bind
residu
activ
site
entranc
affect
subtyp
select
indic
modif
polar
head
hydrophob
tail
variou
pharmacolog
effect
produc
dual
agonist
activ
pan
agonist
activ
previou
research
use
start
point
mean
core
hop
glide
dock
techniqu
novel
class
dual
agonist
paper
start
rosiglitazon
lead
compound
use
core
hop
approach
polar
head
linker
hydrophob
tail
rosiglitazon
modifi
produc
variou
compound
compound
screen
dock
absorpt
distribut
metabol
excret
toxic
admet
predict
discov
excel
pan
agonist
molecular
dynam
simul
repres
cpd
also
done
studi
bind
detail
figur
crystal
structur
receptor
download
protein
data
bank
pdb
pdb
identif
number
prepar
receptor
perform
protein
prepar
wizard
embed
schroding
process
prepar
receptor
includ
assign
bond
order
ad
hydrogen
treat
metal
treat
disulfid
delet
water
allevi
potenti
steric
clash
adjust
formal
charg
minim
protein
opl
optim
potenti
liquid
simul
forc
refin
protein
limit
valu
root
mean
squar
deviat
rmsd
constraint
origin
ligand
center
redock
bind
site
gener
dock
box
molecular
dock
core
hop
modul
schroding
softwar
use
modifi
polar
head
linker
hydrophob
tail
rosiglitazon
figur
core
hop
dock
algorithm
function
fragmentbas
replac
molecular
first
step
core
hop
defin
point
core
attach
scaffold
perform
defin
combin
step
combinatori
screen
panel
second
step
defin
receptor
grid
file
done
receptor
prepar
panel
third
step
prepar
core
attach
scaffold
use
fragment
databas
deriv
fourth
step
align
dock
entir
molecular
structur
built
core
scaffold
core
sort
filter
good
align
redock
receptor
attach
scaffold
follow
use
dock
score
sort
final
origin
ligand
rosiglitazon
use
posit
control
compound
admet
modul
discoveri
studio
use
predict
pharmacokinet
toxic
compound
figur
take
rosiglitazon
control
compound
file
import
admet
descriptor
modul
toxic
predict
extens
toxic
predict
topkat
modul
respect
obtain
pharmacokinet
toxic
paramet
order
studi
bind
stabil
compound
ppar
activ
site
molecular
dynam
simul
perform
use
open
gromac
packag
linux
figur
simul
coordin
file
topolog
file
water
box
construct
fill
simpl
point
charg
water
solut
neutral
sodium
ion
chlorid
energi
minim
system
perform
use
steepest
descend
method
nvt
constant
number
volum
temperatur
ensembl
use
temperatur
maintain
k
cutoff
radiu
van
der
waal
interact
nm
particl
mesh
ewald
algorithm
use
electrostat
linear
constraint
solver
algorithm
use
bond
xray
crystallographi
studi
show
ligand
bind
domain
ppar
compos
antiparallel
three
subtyp
ppar
sequenc
similar
rmsd
atom
addit
ligand
bind
domain
form
yshape
hydrophob
pocket
volum
region
helix
play
import
role
process
activ
ppar
region
significantli
narrow
suitabl
bind
ligand
larger
polar
total
compound
obtain
core
hop
rosiglitazon
compound
dock
pdb
pdb
pdb
respect
screen
compound
higher
dock
score
better
bind
pose
origin
ligand
admet
predict
studi
produc
top
eight
compound
tabl
dock
score
compound
higher
origin
ligand
rosiglitazon
respect
dock
score
compound
somewhat
lower
origin
ligand
addit
hydrogen
bond
distanc
compound
ppar
valu
equal
origin
ligand
dock
mode
repres
cpd
activ
site
receptor
shown
figur
carboxyl
acid
head
cpd
form
hydrogen
bond
key
residu
receptor
respect
aromat
hydrophob
tail
linker
cpd
bound
similar
conform
origin
ligand
rosiglitazon
respect
develop
dual
agonist
muraglitazar
discontinu
clinic
trial
danger
mortal
rate
cardiovascular
thu
predict
drug
admetox
crucial
could
reduc
risk
drug
develop
pharmacokinet
toxic
top
eight
compound
predict
use
admet
modul
discoveri
studio
molecular
weight
mw
partit
coeffici
polar
surfac
area
aqueou
solubl
qplog
number
hydrogen
bond
acceptor
non
number
hydrogen
bond
donor
nohnh
mutagen
rosiglitazon
analogu
list
tabl
respect
compound
accord
lipinski
rule
five
molmw
nohnh
non
qplog
valu
equal
posit
control
rosiglitazon
probabl
mutagen
compound
also
lower
rosiglitazon
order
studi
dynam
behavior
bind
stabil
complex
molecular
dynam
simul
perform
ligand
complex
complex
rmsd
versu
simul
time
consid
signific
criterion
evalu
stabil
dynam
behavior
final
rmsd
valu
simul
system
nm
figur
rmsd
valu
cpd
system
red
lowest
one
among
three
simul
trajectori
order
studi
dynam
detail
key
residu
interact
ligand
root
mean
squar
fluctuat
rmsf
side
chain
residu
obtain
rmsf
curv
complex
similar
ligand
complex
figur
key
residu
pink
area
conch
area
cyan
area
coral
area
rmsf
valu
complex
somewhat
lower
ligand
complex
form
similar
circumst
exist
molecular
dynam
simul
trajectori
indic
ppar
becam
stabl
bind
cpd
studi
rosiglitazon
modifi
core
hop
strategi
produc
variou
analogu
use
dock
admet
predict
techniqu
eight
novel
compound
identifi
multitarget
pan
agonist
excel
pharmacokinet
properti
molecular
dynam
simul
repres
cpd
show
cpd
bound
steadili
activ
site
restrict
target
movement
compound
report
literatur
could
act
novel
ppar
multitarget
agonist
antidiabet
drug
research
